Spironolactone prevents Na+/H+ exchange enhancement in primary aldosteronism

American Journal of Hypertension

Volumn 10, Issue 3, 1997, Pages 341-345

  Koren, Wladimir ^a   Koldanov, Robert ^a   Postnov, Ilya Yu ^a   Postnov, Yuvenaly V ^a  

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

Author keywords

aldosterone; essential hypertension; Na+ H+ antiport; primary aldosteronism; red blood cells; spironolactone

Indexed keywords

ALDOSTERONE ANTAGONIST; SPIRONOLACTONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ERYTHROCYTE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERALDOSTERONISM; MALE; PRIORITY JOURNAL; PROTON SODIUM EXCHANGE;

EID: 0030936507     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(96)00394-9     Document Type: Article

References (14)

1. + antiporter cDNAs from human tissues. Am J Physiol. 262:1992;C1069-C1076.
2. + antiporter. Cell. 56:1989;271-280.
3. Rosskopf D, Duesing R, Siffert W. Membrane sodium-proton exchange and primary hypertension. Hypertension. 21:1993;607-617.
4. Canessa M, Morgan K, Goldszer R, et al. Kinetic abnormalities of the red blood cell sodium-proton exchange in hypertensive patients. Hypertension. 17:1991;340-348.
5. + exchange in erythrocytes of patients with arterial hypertension (abst), in Abstracts of the 4th International Symposium on Hypertension in the Community. Jerusalem, 1992, p 83.
6. + exchange and other ion-transport systems in erythrocytes of essential hypertensives and spontaneously hypertenstive rats: a comparative analysis. J Hypertens. 7:1989;781-789.
7. Arterial hypertension. WHO Technical Reports Series. 628:1978;7-11.
8. + exchange system. J Memb Biol. 90:1986;21-28.
9. + exchange rate and more alkaline intracellular pH set-point in essential hypertension: effect of protein kinase modulation in platelets. J Hypertens. 9:1991;1013-1019.
10. + antiport in essential hypertension. J Hypertens. 8:1990;533-537.
11. Postnov YuV, Orlov SN. Primary Hypertension as Cell Membrane Pathology. 1987;Meditsina Publishers, Moscow.
12. Overdiek HWPM. New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther. 38:1985;469-474.
13. Skluth HA, Gums JF. Spironolactone: a re-examination. DICP Ann Pharmacother. 24:1990;52-59.
14. Alonso A, Arrazola A, Garciandia A, et al. Erythrocyte anion exchanger activity and intracellular pH in essential hypertension. Hypertension. 22:1993;348-356.